1306763-24-5

Basic information

• Product Name: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile
• Synonyms: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile;1H-Indene-4-carbonitrile, 2,3-dihydro-1-hydroxy-, (1R)-
• CAS NO: 1306763-24-5
• Molecular Formula: C10H9NO
• Molecular Weight: 159.18456
• Mol File: 1306763-24-5.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(1306763-24-5)
• EPA Substance Registry System: (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile(1306763-24-5)

Safety Data

• Hazardous Substances Data: 1306763-24-5(Hazardous Substances Data)

Usage

General Description

(1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile is a chemical compound with the molecular formula C10H9NO. It is a derivative of indene, which is a bicyclic aromatic hydrocarbon. The compound contains a hydroxy group and a carbonitrile group, giving it potential for use in organic synthesis and pharmaceutical development. The (1R) designation indicates the stereochemistry of the molecule, with the hydroxy group located on the first carbon of the indene ring. (1R)-1-hydroxy-2,3-dihydro-1H-indene-4-carbonitrile may have applications in the development of pharmaceuticals or as a reagent in organic chemical reactions due to its unique structure and functional groups.

Upstream product

• 60899-34-5 4-cyano-2,3-dihydro-1H-inden-1-one 
• 25724-79-2 5-cyano-1-indanone 
• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 

Downstream Products

• 1307230-43-8 4-(5-(3,4-diethoxybenzyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1306763-71-2 (S)-tert-butyl 4-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylcarbamate 
• 1201446-74-3 N₁-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-N₂,N₂-diethylethane-1,2-diamine 
• 1094042-01-9 CYM-5442 
• 1201446-43-6 4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-one 
• 1093827-52-1 (±)-4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201447-94-0 4-(5-(4-ethoxy-3-nitrophenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201447-11-1 2-(4-(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylamino)ethanol 
• 1201447-09-7 2-(4-(5-(4-isopropoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ylamino)ethanol 
• 1201447-07-5 2-ethoxy-5-(3-(1-hydroxy-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)benzonitrile 
• 1201447-03-1 4-(5-(4-ethoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 
• 1201447-01-9 4-(5-(4-isopropoxy-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-ol 

Relevant articles and documents

Enantioselective Synthesis of Ozanimod, the Active Pharmaceutical Ingredient of a New Drug for Multiple Sclerosis

We report here a short enantioselective synthesis of Ozanimod, a potent modulator of the enzyme Sphingosine-1-phosphate receptor (S1PR), recently approved by FDA and EMA for the treatment of relapsing-remitting multiple sclerosis. Amongst different synthetic approaches explored, we achieved the best result introducing the stereogenic centre in the last step through imine asymmetric transfer hydrogenation (ATH) using Wills’ catalysts. Besides the reduced numbers of enantiomeric purity controls required, this process culminates in an exceptionally high enantioselective reductive amination obtained with commercially available tethered Ru catalysts. Starting from commercially available 4-cyano-indanone, enantiomerically pure Ozanimod was obtained in 5 steps in 62 % overall yield and 99 % ee.

Method for preparing (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile

The invention discloses a method for preparing (S)-1-amino-2,3-dihydro-1H-indene-4-carbonitrile. The method comprises the following steps: 1, adding 4-cyano-1-indanone to tetrahydrofuran, adding (S)-2-methyl-CBS-oxazaborolidine, cooling the obtained solut

HETERCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Described herein are heterocyclic compounds, compositions, and methods for their use for treatment of disease.